Literature DB >> 16552400

Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women.

I T Gram1, T Norat, S Rinaldi, L Dossus, A Lukanova, B Téhard, F Clavel-Chapelon, C H van Gils, P A H van Noord, P H M Peeters, H B Bueno-de-Mesquita, G Nagel, J Linseisen, P H Lahmann, H Boeing, D Palli, C Sacerdote, S Panico, R Tumino, S Sieri, M Dorronsoro, J R Quirós, C A Navarro, A Barricarte, M-J Tormo, C A González, K Overvad, S Paaske Johnsen, A Olsen, A Tjønneland, R Travis, N Allen, S Bingham, K-T Khaw, P Stattin, A Trichopoulou, V Kalapothaki, T Psaltopoulou, C Casagrande, E Riboli, R Kaaks.   

Abstract

OBJECTIVE: To examine the relationship between body mass index (BMI) and waist-hip ratio (WHR) with serum levels of insulin-like growth factor-I (IGF-I), and its binding protein (IGFBP)-3.
DESIGN: Cross-sectional study on 2139 women participating in a case-control study on breast cancer and endogenous hormones. Data on lifestyle and reproductive factors were collected by means of questionnaires. Body height, weight, waist and hip circumferences were measured. Serum levels of IGF-I and insulin-like binding protein (IGFBP)-3 were measured by enzyme-linked immunosorbent assays. Adjusted mean levels of IGF-I and IGFBP-3 across quintiles of BMI, waist circumference, and WHR were calculated by linear regression. Results were adjusted for potential confounders associated with IGF-I and IGFBP-3.
RESULTS: Adjusted mean serum IGF-I values were lower in women with BMI<22.5 kg/m(2) or BMI>29.2 kg/m(2) compared to women with BMI within this range (P(heterogeneity)<0.0001, P(trend)=0.35). Insulin-like growth factor-I was not related to WHR after adjustment for BMI. IGF-binding protein-3 was linearly positively related to waist and WHR after mutual adjustment. The molar ratio IGF-I/IGFBP-3 had a non-linear relation with BMI and a linear inverse relationship with WHR (P (trend)=0.005).
CONCLUSIONS: Our data confirm the nonlinear relationship of circulating IGF-I to total adiposity in women. Serum IGFBP-3 was positively related to central adiposity. These suggest that bioavailable IGF-I levels could be lower in obese compared to non-obese women and inversely related to central adiposity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552400     DOI: 10.1038/sj.ijo.0803324

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  24 in total

1.  The women in steady exercise research (WISER) survivor trial: The innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema.

Authors:  Renate M Winkels; Kathleen M Sturgeon; Michael J Kallan; Lorraine T Dean; Zi Zhang; Margaret Evangelisti; Justin C Brown; David B Sarwer; Andrea B Troxel; Crystal Denlinger; Monica Laudermilk; Anna Fornash; Angela DeMichele; Lewis A Chodosh; Kathryn H Schmitz
Journal:  Contemp Clin Trials       Date:  2017-07-21       Impact factor: 2.226

2.  Genotypes and haplotypes in the insulin-like growth factors, their receptors and binding proteins in relation to plasma metabolic levels and mammographic density.

Authors:  Margarethe Biong; Inger T Gram; Ilene Brill; Fredrik Johansen; Hiroko K Solvang; Grethe I G Alnaes; Toril Fagerheim; Yngve Bremnes; Stephen J Chanock; Laurie Burdett; Meredith Yeager; Giske Ursin; Vessela N Kristensen
Journal:  BMC Med Genomics       Date:  2010-03-19       Impact factor: 3.063

3.  Effects of Bariatric Surgery on Change of Brown Adipocyte Tissue and Energy Metabolism in Obese Mice.

Authors:  Yuanwen Chen; Jianjun Yang; Xin Nie; Zhicheng Song; Yan Gu
Journal:  Obes Surg       Date:  2018-03       Impact factor: 4.129

4.  Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels by race/ethnicity and gender.

Authors:  Jessica M Faupel-Badger; David Berrigan; Rachel Ballard-Barbash; Nancy Potischman
Journal:  Ann Epidemiol       Date:  2009-12       Impact factor: 3.797

5.  Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3.

Authors:  Jay H Fowke; Charles E Matthews; Herbert Yu; Qiuyin Cai; Sarah Cohen; Maciej S Buchowski; Wei Zheng; William J Blot
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

6.  Circulating concentrations of insulin-like growth factor-I, insulin-like growth factor-binding protein-3, genetic polymorphisms and mammographic density in premenopausal Mexican women: results from the ESMaestras cohort.

Authors:  S Rinaldi; C Biessy; M Hernandez; F Lesueur; I dos-Santos-Silva; M S Rice; M Lajous; R Lopez-Ridaura; G Torres-Mejía; I Romieu
Journal:  Int J Cancer       Date:  2013-10-05       Impact factor: 7.396

7.  Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.

Authors:  Helen Swede; Thomas E Rohan; Herbert Yu; Joseph C Anderson; Richard G Stevens; Jane Brokaw; Joel Levine; Bruce M Brenner; Carl D Malchoff; Valerie B Duffy; Devon C Pleau; Daniel W Rosenberg
Journal:  Cancer Causes Control       Date:  2008-12-09       Impact factor: 2.506

8.  Androgens may mediate a relative preservation of IGF-I levels in overweight and obese women despite reduced growth hormone secretion.

Authors:  A L Utz; A Yamamoto; P Sluss; J Breu; K K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-07-22       Impact factor: 5.958

9.  Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank.

Authors:  Hannah Oh; Ruth M Pfeiffer; Roni T Falk; Hisani N Horne; Jackie Xiang; Michael Pollak; Louise A Brinton; Anna Maria V Storniolo; Mark E Sherman; Gretchen L Gierach; Jonine D Figueroa
Journal:  Int J Cancer       Date:  2018-04-01       Impact factor: 7.396

10.  Low level of IGF-1 in obesity may be related to obstructive sleep apnea syndrome.

Authors:  Ahmet Ursavas; Mehmet Karadag; Yesim Ozarda Ilcol; Ilker Ercan; Basak Burgazlioglu; Funda Coskun; R Oktay Gozu
Journal:  Lung       Date:  2007-08-27       Impact factor: 3.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.